If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Mechanism of action == Quinupristin and dalfopristin are protein synthesis inhibitors in a synergistic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.
== Commercial and clinical products == The clearest commercial example is the SERI Surgical Scaffold, a knitted mesh of highly purified silk fibroin that originated in research at Tufts University and was first marketed by Serica Technologies. The U.S. Food and Drug Administration cleared it in 2009 as a temporary scaffold for the support and reinforcement of soft tissue; the product was subsequently held by Allergan and then by Sofregen Medical. After implantation the mesh provides immediate mechanical support and is gradually resorbed and replaced by the patient's own collagen. Silk sutures remain in widespread clinical use, and other silk-based products and devices are in development or early clinical testing.
Tonic water is often used as a drink mixer for cocktails, especially gin and tonic. Vodka tonic is also popular. Tonic water with lemon or lime juice added is often known as bitter lemon or bitter lime. It is popular for its signature bittersweet taste. Another use of tonic water is in coffee. The espresso and tonic was created in Helsingborg, Sweden, at Koppi Roasters after a staff party where they mixed tonic water, syrup, and an espresso. Since 2007, the drink has grown in popularity in Scandinavia, Europe, and the United States.
Less than 5% of the power consumed by a typical tungsten incandescent light bulb is converted into visible light, with most of the rest being emitted as invisible infrared radiation. Some applications make use of the emitted infrared radiation, such as heat lamps in incubators, lava lamps, Edison effect bulbs, and the Easy-Bake Oven toy. Quartz envelope halogen infrared heaters are used for industrial processes such as paint curing and space heating. Light bulbs are rated by their luminous efficacy, which is the ratio of the amount of visible light emitted (luminous flux) to the electrical power consumed. Luminous efficacy is measured in lumens per watt (lm/W). The luminous efficiency of a source is defined as the ratio of its luminous efficacy to the maximum possible luminous efficacy, which is 683 lm/W. An ideal white light source could produce about 250 lumens per watt, corresponding to a luminous efficiency of 37%. For a given quantity of light, an incandescent light bulb consumes more power and emits more heat than most other types of electric light. In buildings where air conditioning is used, incandescent lamps' heat output increases load on the air conditioning system. While heat from lights will reduce the need to run a building's heating system, the latter can usually produce the same amount of heat at lower cost than incandescent lights. The chart below lists the luminous efficacy and efficiency for several types of incandescent bulb. A longer chart in luminous efficacy compares a broader array of light sources.
The Cuban Freemasons started shouting "Hold my Cuba Libra!" Filema Duarte's decision was later supported by the Cuban Ministry of Justice and the Communist Party. Also supporting Filema Duarte's decision were Grand Secretary Juliannys Galano, Grand Treasurer Juan Carlos Yero, and the President of the Supreme Court of Masonic Justice, Rancel Montero. After the suspended meeting, pressure mounted on the office of the Grand Master. Filema Duarte announced another session of the Grand Lodge would occur in May. However, he canceled this meeting after receiving what he called threats against his person. Government agents from the Office of Associations then interrogated members who had called for the Grand Master's removal. These interrogations did not concern Filema Duarte; the government was attempting to gather evidence for a case on Grand Commander Viñas Alonso. The Office of Associations informed these Freemasons that Viñas Alonso was occupying the office of Grand Commander illegally, and that they had to elect a new Grand Commander. One Cuban Freemason later told journalists: "It is the plinth of cynicism, Viñas Alonso isn't the problem! We need to get rid of Filema Duarte! Filema Duarte is a stone in his shoes."
Sources: en.wikipedia.org
=== Effects on behaviour === Octopuses such as Abdopus aculeatus can survive the loss of an arm (tentacle) but suffer long-term behavioural changes and hypersensitivity afterwards. The species makes use of autotomy, the self-amputation of an arm, as an anti-predator defence. Crush injury to an arm caused the animals to eject ink, to squirt a jet of water, to groom the wound, and later to retract the injured arm and guard it with other arms.
== Coding and Homology == The very first nucleotide sequence of the gene encoding for the beta subunit of human chorionic gonadotropin (CGB) suggests that CGB evolved from a duplicate copy of the beta subunit of LH, another glycoprotein hormone with significant influence over pregnancy, expressed in the anterior pituitary gland. Subsequent nuclear mapping has found that humans possess six copies of the CGB gene, amazingly found together with the LHB gene on chromosome 19q13.33. Human CGB and LHB genes share an extremely high degree of similarity in their sequences, clocking in at 94% similarity. This nucleotide sequence is encompassed by 3 exons. Of the six genes that encode for CGB, four of them are functional. These include CGB, CGB5, CGB7, and CGB8. These four genes share a 97-99% DNA sequence similarity, and code for the biochemically functional beta subunit of hCG. Although CGB1 and CGB2 genes are similar in sequence to the other four genes previously mentioned (85%), they encode for a novel hypothetical protein that is 132 amino acids in length and does not share any homology to the functional CGB subunit. This particular result was caused by a DNA fragment insertion into the 5' untranslated region (UTR) of the CGB1 and CGB2 genes, giving way to a novel exon one and creating a single basepair open reading frame shift for exons two and three.
==== Tests for pigments ==== In October 1978 a team of scientists affiliated with STURP took 32 samples from the surface of the Shroud, using adhesive tape. Of those samples, 18 were taken from areas of the Shroud that showed a body or blood image, while 14 were taken from non-image areas. The chemical microscopist Walter McCrone, a leading expert in the forensic authentication of historical documents and works of art, examined the tapes using polarized light microscopy and other physical and chemical techniques. McCrone concluded that the Shroud's body image had been painted with a dilute pigment of red ochre (a form of iron oxide) in a collagen tempera (i.e., gelatin) medium, using a technique similar to the grisaille employed in the 14th century by Simone Martini and other European artists. McCrone also found that the "bloodstains" in the image had been highlighted with vermilion (a bright red pigment made from mercury sulfide), also in a collagen tempera medium. McCrone reported that no actual blood was present in the samples taken from the Shroud. Other members of STURP rejected McCrone's conclusions and concluded, based on their own examination of the Shroud and the tape samples, that the image on the Shroud could not be explained by the presence of pigments. Mark Anderson, who was working for McCrone, analyzed the Shroud samples. In his book, chemist Raymond Rogers states that Anderson, who was McCrone's Raman microscopy expert, concluded that the samples acted as organic material when he subjected them to the laser.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
David Andrew Jerome Samberg (born August 18, 1978) is an American actor, comedian, rapper, writer and producer. He is a member of the comedy music group the Lonely Island, along with childhood friends Akiva Schaffer and Jorma Taccone. Samberg was also a cast member and writer for the NBC sketch comedy series Saturday Night Live from 2005 to 2012, where he and his fellow group members are credited with popularizing the SNL Digital Shorts. Samberg's starring film roles include Hot Rod (2007), That's My Boy (2012), Celeste and Jesse Forever (2012), Popstar: Never Stop Never Stopping (2016), and Palm Springs (2020). He has voiced roles in Space Chimps (2008), the Cloudy with a Chance of Meatballs film series (2009–present), the Hotel Transylvania film series (2012–present), Storks (2016), Chip 'n Dale: Rescue Rangers (2022), Spider-Man: Across the Spider-Verse (2023), and Zootopia 2 (2025). From 2013 to 2021, he portrayed Jake Peralta in the Fox/NBC police procedural sitcom series Brooklyn Nine-Nine, which he also produced. For his work on the show, he was awarded a Golden Globe Award for Best Actor – Television Series Musical or Comedy in 2013.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.